^
    Back
    Association details:
    Biomarker:ERBB3 expression
    Cancer:Colorectal Cancer
    Drug:patritumab deruxtecan (U3-1402) (Topoisomerase I inhibitor, HER3-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Study of U3-1402 in subjects with colorectal cancer

    Excerpt:
    ...Willing to provide a required pre-treatment tumor biopsy and anadditional archival tissue sample for the assessment of HER3 expression levels by IHC and exploratory biomarkers, defined as: a. Pre-treatment tumor biopsy. ...
    Trial ID:
    2019-004418-32
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer

    Excerpt:
    ...- Willing to provide a required pre-treatment tumor biopsy and an additional archival tissue sample for the assessment of HER3 expression levels by immunohistochemistry and exploratory biomarkers, defined as: 1....
    Trial ID:
    NCT04479436
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    / 26 - HER3-targeting antibody-drug conjugate, U3-1402, induces tumor regression in a variety of xenograft models and exerts enhanced antitumor activity by combining with PI3K inhibition Add to My Itinerary

    Published date:
    05/15/2020
    Excerpt:
    Antitumor activity of U3-1402 was assessed in various xenograft models of human cancers, including breast, lung, and colorectal cancers, and melanoma....U3-1402 may exert potent antitumor activity in various human cancer cells expressing HER3, and its efficacy is likely to be enriched by HER3 expression.